Neurocrine Biosciences (NBIX) Other Gross PP&E Adjustments (2016 - 2025)
Neurocrine Biosciences (NBIX) has disclosed Other Gross PP&E Adjustments for 14 consecutive years, with -$247.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 22.79% year-over-year to -$247.3 million, compared with a TTM value of -$247.3 million through Dec 2025, up 22.79%, and an annual FY2025 reading of -$247.3 million, up 22.79% over the prior year.
- Other Gross PP&E Adjustments was -$247.3 million for Q4 2025 at Neurocrine Biosciences, up from -$468.9 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$45.2 million in Q4 2023 and bottomed at -$502.2 million in Q1 2025.
- Average Other Gross PP&E Adjustments over 4 years is -$227.8 million, with a median of -$247.3 million recorded in 2025.
- The sharpest move saw Other Gross PP&E Adjustments plummeted 608.63% in 2024, then grew 22.79% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at -$97.9 million in 2021, then soared by 53.83% to -$45.2 million in 2023, then tumbled by 608.63% to -$320.3 million in 2024, then increased by 22.79% to -$247.3 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for NBIX at -$247.3 million in Q4 2025, -$468.9 million in Q3 2025, and -$492.3 million in Q2 2025.